BioNTech SE (BNTX.VI)
Develops mRNA vaccines and cancer treatments using genetic technology.
80.90+0.00%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-12.1%
The outlook
BioNTech is trading near the lower end of its 52-week range, currently about 35% of the way up from its low. The stock sits mixed relative to its moving averages, suggesting no clear directional momentum. Analyst coverage appears thin, and the overall sentiment leans neutral.
What’s behind the score
Price trendMixed vs its moving averages
52-week range35% of the way from its 52-week low to high
Market cap
$20.46B
52-wk high
104.00
52-wk low
68.65
50-day avg
79.63
200-day avg
84.76
Trailing P/E
—